C.R. Bard Inc. (BCR) Shares Bought by BTIM Corp.
BTIM Corp. boosted its stake in shares of C.R. Bard Inc. (NYSE:BCR) by 1.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 353,036 shares of the company’s stock after buying an additional 4,843 shares during the period. C.R. Bard accounts for 1.3% of BTIM Corp.’s investment portfolio, making the stock its 6th largest position. BTIM Corp. owned about 0.48% of C.R. Bard worth $79,179,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in BCR. Standard Life Investments LTD acquired a new stake in C.R. Bard during the second quarter valued at about $241,642,000. Mycio Wealth Partners LLC boosted its stake in C.R. Bard by 36.4% in the second quarter. Mycio Wealth Partners LLC now owns 599 shares of the company’s stock valued at $141,000 after buying an additional 160 shares during the period. Fundsmith LLP boosted its stake in C.R. Bard by 24.7% in the second quarter. Fundsmith LLP now owns 2,197,626 shares of the company’s stock valued at $516,220,000 after buying an additional 435,595 shares during the period. Todd Asset Management LLC acquired a new stake in C.R. Bard during the second quarter valued at about $15,973,000. Finally, Meag Munich Ergo Kapitalanlagegesellschaft MBH acquired a new stake in C.R. Bard during the second quarter valued at about $12,496,000. Institutional investors and hedge funds own 86.74% of the company’s stock.
Shares of C.R. Bard Inc. (NYSE:BCR) opened at 215.88 on Wednesday. C.R. Bard Inc. has a one year low of $172.21 and a one year high of $239.43. The firm’s 50-day moving average price is $216.43 and its 200-day moving average price is $222.44. The stock has a market capitalization of $15.87 billion, a P/E ratio of 32.61 and a beta of 0.67.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Tuesday, October 25th. The company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.55 by $0.09. The company earned $941.90 million during the quarter, compared to analysts’ expectations of $931.66 million. C.R. Bard had a net margin of 14.05% and a return on equity of 48.13%. C.R. Bard’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.28 earnings per share. Equities research analysts anticipate that C.R. Bard Inc. will post $10.27 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, November 4th. Shareholders of record on Monday, October 24th were given a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, October 20th. This represents a $1.04 annualized dividend and a yield of 0.48%. C.R. Bard’s payout ratio is presently 15.48%.
COPYRIGHT VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/30/c-r-bard-inc-bcr-shares-bought-by-btim-corp.html.
BCR has been the subject of several recent analyst reports. Zacks Investment Research cut C.R. Bard from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Evercore ISI initiated coverage on C.R. Bard in a research note on Thursday, September 15th. They set a “buy” rating and a $235.00 target price for the company. Wells Fargo & Co. raised C.R. Bard from a “market perform” rating to an “outperform” rating in a research note on Friday, September 16th. Jefferies Group reissued a “hold” rating and set a $237.00 target price on shares of C.R. Bard in a research note on Tuesday, September 27th. Finally, BMO Capital Markets raised C.R. Bard from a “market perform” rating to an “outperform” rating and set a $240.00 target price for the company in a research note on Wednesday, October 26th. They noted that the move was a valuation call. Nine investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $233.07.
In other C.R. Bard news, VP Betty D. Larson sold 4,032 shares of C.R. Bard stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $225.33, for a total transaction of $908,530.56. Following the completion of the sale, the vice president now directly owns 10,298 shares in the company, valued at $2,320,448.34. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP John A. Deford sold 7,928 shares of C.R. Bard stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $221.06, for a total transaction of $1,752,563.68. The disclosure for this sale can be found here. Company insiders own 0.97% of the company’s stock.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.